# FDA Approves ANDA for Somerset Therapeutics Somerset Therapeutics LLC has received FDA approval for an abbreviated new drug application (ANDA219529), expanding its generic drug portfolio and positioning the company to capture additional market share in the competitive generic pharmaceuticals sector. The approval strengthens Somerset's competitive standing and allows the manufacturer to offer patients more affordable therapeutic options across its product lineup.